trending Market Intelligence /marketintelligence/en/news-insights/trending/uDGhj90yhPduqzsxYC6AYQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca's Imfinzi approved in China for non-small cell lung cancer subtype

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

AstraZeneca's Imfinzi approved in China for non-small cell lung cancer subtype

AstraZeneca PLC's medicine Imfinzi was approved in China to treat certain patients with non-small cell lung cancer.

China's National Medical Products Administration approved Imfinzi, or durvalumab, to treat patients with stage 3 non-small cell lung cancer whose tumors cannot be removed through surgery. These patients should have also received platinum-based chemotherapy and radiation therapy following which their disease has not progressed.

Stage 3 non-small cell lung cancer is defined by how much the cancer has spread to nearby tissues.

The U.K.-based pharmaceutical giant said the approval was backed by data from a phase 3 trial, dubbed Pacific, which showed the drug extended patients' lives longer than placebo.

Imfinzi is already approved for treating patients with this particular type of lung cancer in over 54 countries, including the U.S., EU and Japan. The medicine is also approved in 11 countries, including the U.S., to treat patients with advanced bladder cancer.